Short answer
Cogent Biosciences, Inc. (COGT) filed its fiscal 2025 10-K annual report with the SEC on Feb 17, 2026.
- Top risk flagged: Regulatory risk: FDA NDA submissions for bezuclastinib in NonAdvSM (2025) and GIST (expected April 2026) may face approval delays or rejections
FY2025 key financial metrics · XBRL
- Net income
- −$329M
- −28.6% YoY
- EPS (diluted)
- −$2.16
- −11.3% YoY
- ROE
- -51.7%
- +48.1 pp YoY
- Operating cash flow
- −$264M
- −27.3% YoY
Source: XBRL data from the Cogent Biosciences, Inc. (COGT) FY2025 10-K on SEC EDGAR. USD.
Cogent Biosciences, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Clinical-stage biotech developing precision therapies targeting genetically defined diseases, focusing mainly on tyrosine kinase inhibitors like bezuclastinib
- New emphasis: Positive top-line Phase 2/3 results in 2025 for bezuclastinib in Non-Advanced/Advanced Systemic Mastocytosis and GIST; expecting U.S. launches in H2 2026
- Strategic shift: Building internal U.S. commercial organization for bezuclastinib launch, alongside advancing Phase 1 studies for FGFR2/3 and mutant ErbB2 inhibitors, and progressing PI3Kα, KRAS, JAK2 preclinicals
- Quantitative highlight: PEAK trial median PFS 16.5 months with bezuclastinib plus sunitinib vs. 9.2 months sunitinib alone; 50% risk reduction in progression or death
- Noteworthy: FDA granted Breakthrough Therapy Designations for bezuclastinib in multiple indications and accepted NDAs under expedited review programs in 2025-2026
Management Discussion & Analysis
- Net loss $328.9M in 2025 vs $255.9M in 2024, increase of $73M; no product revenue generated
- R&D expense $269.8M in 2025 vs $232.7M in 2024, up $37.1M; G&A $63.6M vs $43.3M, up $20.3M
- Bezuclastinib trials expenses flat at ~$120M; early-stage programs +$12M; personnel costs +$21.1M including $4.1M stock comp
- Cash, cash equivalents, and marketable securities $900.8M as of Dec 31, 2025, sufficient to fund operations into 2028
- Management expects increased expenses for regulatory approvals, commercial launch, manufacturing, and pipeline expansion
Risk Factors
- Regulatory risk: FDA NDA submissions for bezuclastinib in NonAdvSM (2025) and GIST (expected April 2026) may face approval delays or rejections
- Macroeconomic threat: U.S. healthcare pricing pressure from May 2025 White House Most Favored Nation drug pricing policy impacting reimbursement
- Supply chain vulnerability: Dependence on CMOs for clinical trial materials; CMO failure could delay trials and force costly in-house manufacturing
- Competitive risk: Competition from larger pharma and biotech firms with greater resources and faster FDA approvals for precision medicines targeting same diseases
- Financial risk: Need for substantial investment in commercial manufacturing capacity and marketing before generating bezuclastinib revenue
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.